On Sept. 14, 2020, Meridian Bioscience announced the launch of a novel highly sensitive SARS-CoV-2 antibody pair to the trimeric spike protein to accelerate development of COVID-19 assays from patient saliva. Coronavirus-neutralizing antibodies primarily target the trimeric spike (S) glycoprotein on the viral surface that mediates entry into the host cell. This antibody pair binds to recombinant SARS-CoV-2 trimeric spike protein.